November 9, 2018 PR/Corporate

Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of November 6, 2018, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to 16 individuals entering into employment with Fluidigm. The equity awards were... Read more

November 7, 2018 PR/Corporate

Fluidigm Recognized as a Company to Watch in 2019

PDF Version Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — BioInformatics Inc., the leading research and advisory firm serving the life science tool market, today announced Fluidigm as the Company to Watch in 2019 at the biannual Life Science Industry Awards® (LSIA). Designed as people’s choice awards, LSIA has been... Read more

October 31, 2018 PR/Corporate

Laura Clague Named to Fluidigm Board of Directors

PDF Version Senior Financial Leader with Broad Corporate and Biotech Expertise SOUTH SAN FRANCISCO, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Laura M. Clague to the company’s Board of Directors and its audit committee. Clague is Chief Financial Officer of Retrophin, Inc., with more than 30 years of experience as a senior financial executive.... Read more

October 25, 2018 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System

PDF Version Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, today announced the publication of the 10,000 Immunomes Project (10KIP), a seminal human immune reference standard containing mass cytometry immune cell profiles,... Read more

October 4, 2018 Informatics & Software Life Science Tools M&A, Partnerships

Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD

PDF Version Combining high-performance automated microfluidics with easy-to-use software to streamline CNV detection for translational and clinical research SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a non-exclusive distribution agreement with DNA Software, Inc. to provide CopyCount-CNV™ software for use with the Fluidigm Biomark™ HD system. Copy number variation... Read more

August 9, 2018 Cell Analysis Tools PR/Corporate

Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting

PDF Version Leading translational and clinical researchers to share new insights and best practices using Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced it will hold its 2nd Annual Imaging Mass Cytometry User Group Meeting September 10–11 at the Seattle Art Museum. In this... Read more

August 6, 2018 PR/Corporate

Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of July 31, 2018, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to eight individuals entering into employment with Fluidigm. The equity... Read more

June 26, 2018 Cell Analysis Tools Life Science Tools PR/Corporate

David King Joins Fluidigm as Vice President, Research and Development, Genomics

SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, King will drive R&D strategy and execution for all genomics products and systems across the company. “Fluidigm is a leader... Read more

June 7, 2018 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service

Joint offering enables acceleration of genomic panel design for translational and clinical disease research SOUTH SAN FRANCISCO, Calif., June 07, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation announced today that it has entered into a co-marketing agreement with Genomenon to offer evidence-based genomic panel design services for translational and clinical disease research. The rapidly expanding knowledge base of genes and... Read more

June 5, 2018 Life Science Tools Product Launch

Fluidigm Releases Sample Identification Genotyping Panel for Translational and Clinical Research

Standardizing human sample identification using automated genomic microfluidic systems that reduce hands-on time and cost per sample SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ Sample ID Genotyping Panel for the identification and quality assessment of human samples and cell lines in disease research. Maintaining accurate chain-of-custody from sample... Read more